Paper 79 - PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

Author(s)

• WT

  William D. Tap, MD

  Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
  New York, New York, United States

  Slides

Co-Author(s)

• SS

  Silvia Stacchiotti, MD

  Medical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• AI

  Antoine Italiano, MD, PhD

  Institut Bergonié
  Bordeaux, Aquitaine, France
• JT

  Jonathan Trent, MD, PhD

  Sylvester Comprehensive Cancer Center, University of Miami Health System
  Miami, Florida, United States
• IT

  Ilona Tala, PhD

  Servier Bio-Innovation
  Boston, Massachusetts, United States
• ZQ

  Zhe Qu, PhD

  Servier Bio-Innovation
  Boston, Massachusetts, United States
• 

  Diego A. Gianolio, PhD (he/him/his)

  Sr. Director Clinical Science
  Servier Bio-Innovation
  Boston, Massachusetts, United States
• CD

  Channa Debruyne, MD

  Servier R&D
  Brussels, Brussels Hoofdstedelijk Gewest, Belgium
• JB

  Jean-Yves Blay, MD, PhD

  Centre Léon Bérard
  Lyon, Rhone-Alpes, France
• AW

  Andrew J. Wagner, MD, PhD

  MD, PhD
  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States